William Mitchell

 William Marvin Mitchell, M.D., Ph.D. was appointed the Chairman of the Board of Hemispherx Biopharma, the maker of Ampligen in February 2016 after serving as a Director since July 1998. Dr. Mitchell is a Professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, Nashville, Tennessee, and is a board certified physician. He replaced Dr. William Carter, the founder of the company and the inventor of Ampligen.

Notable studies

 * 1995, Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen (Abstract)
 * 2007, Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
 * 2015, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod
 * 2016, William M. Mitchell published a review in the journal, Expert Review of Clinical Pharmacology that stated: "Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe."
 * 2017, Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy